[Form 4] BioAge Labs, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BioAge Labs' Chief Medical Officer reported an insider transaction involving 18,000 shares of common stock on December 9, 2025. The officer exercised stock options to buy 18,000 shares at $6.57 per share and then sold the same 18,000 shares at $12 per share, resulting in no directly held common stock after the sale.

The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024. Following the exercise, the officer continues to hold 9,383 stock options with a $6.57 exercise price, which vest in 1/48th monthly installments that began on April 1, 2022, and have an expiration date of May 28, 2032.

Insider Trade Summary

Net Seller: 18,000 shares ($216,000)

Net Sell 3 txns

Insider RUBIN PAUL D

Role Chief Medical Officer

Sold 18,000 shs ($216K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	18,000	$0.00	--
Exercise	Common Stock	18,000	$6.57	$118K
Sale	Common Stock	18,000	$12.00	$216K

Holdings After Transaction: Stock Option (Right to Buy) — 9,383 shares (Direct); Common Stock — 18,000 shares (Direct)

Footnotes (1)

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBIN PAUL D

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M(1)		18,000	A	$6.57	18,000	D
Common Stock	12/09/2025		S(1)		18,000	D	$12	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.57	12/09/2025		M(1)			18,000	(2)	05/28/2032	Common Stock	18,000	$0	9,383	D

Explanation of Responses:

1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

2. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioAge Labs (BIOA) report on December 9, 2025?

BioAge Labs' Chief Medical Officer exercised options to acquire 18,000 shares of common stock at $6.57 per share and sold 18,000 shares at $12 per share on December 9, 2025, leaving no directly held common stock.

Who is the reporting person in the BioAge Labs (BIOA) insider filing and what is their role?

The reporting person is an officer of BioAge Labs, serving as the company's Chief Medical Officer and filing individually as one reporting person.

At what prices were BioAge Labs (BIOA) shares bought and sold in this insider transaction?

The Chief Medical Officer exercised stock options to buy shares at an exercise price of $6.57 per share and sold the resulting common shares at $12 per share.

How many BioAge Labs (BIOA) stock options remain after the reported transaction?

After exercising part of the award, the officer beneficially owns 9,383 stock options with an exercise price of $6.57 per share.

Was the BioAge Labs (BIOA) insider transaction made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

How do the BioAge Labs (BIOA) stock options held by the CMO vest and when do they expire?

The options vest as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022 and each subsequent tranche on the monthly anniversary, and they carry an expiration date of May 28, 2032.